Merrimack Pharmaceuticals Stock Last Dividend Paid
MACKDelisted Stock | USD 11.96 0.12 1.01% |
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
Merrimack |
Merrimack Pharmaceuticals Company Last Dividend Paid Analysis
Merrimack Pharmaceuticals' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
CompetitionBased on the recorded statements, Merrimack Pharmaceuticals has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Sign In To Macroaxis Now
Sign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modules |
All Next | Launch Module |
Merrimack Fundamentals
Return On Equity | -0.0112 | |||
Return On Asset | -0.0107 | |||
Current Valuation | (20.36 M) | |||
Shares Outstanding | 14.79 M | |||
Shares Owned By Insiders | 1.19 % | |||
Shares Owned By Institutions | 62.97 % | |||
Number Of Shares Shorted | 842.49 K | |||
Price To Earning | 65.70 X | |||
Price To Book | 11.38 X | |||
Gross Profit | (9.1 M) | |||
EBITDA | (2.18 M) | |||
Net Income | (1.18 M) | |||
Cash And Equivalents | 13.36 M | |||
Cash Per Share | 1.00 X | |||
Debt To Equity | 33.90 % | |||
Current Ratio | 31.85 X | |||
Book Value Per Share | 15.25 X | |||
Cash Flow From Operations | (1.52 M) | |||
Short Ratio | 8.65 X | |||
Earnings Per Share | (0.09) X | |||
Price To Earnings To Growth | 0.07 X | |||
Target Price | 4.0 | |||
Beta | 1.42 | |||
Market Capitalization | 223.75 M | |||
Total Asset | 19.19 M | |||
Retained Earnings | (548.82 M) | |||
Working Capital | 18.74 M | |||
Current Asset | 89.62 M | |||
Current Liabilities | 88.28 M | |||
Net Asset | 19.19 M |
About Merrimack Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merrimack Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |